Comparative Pharmacology
Head-to-head clinical analysis: ORUDIS KT versus ORUVAIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORUDIS KT versus ORUVAIL.
ORUDIS KT vs ORUVAIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ketoprofen is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.
50 mg orally three times daily or 75 mg orally twice daily; maximum 300 mg/day.
100 to 200 mg orally twice daily
None Documented
None Documented
Terminal elimination half-life: 2-4 hours (increased in elderly and renal impairment, up to 12 hours).
5-9 hours (terminal elimination half-life); in elderly or renal impairment, may extend up to 20 hours; clinical context: dosing adjustments recommended in renal impairment.
Renal (approximately 60-80% as metabolites, <10% unchanged); biliary/fecal (approximately 20-35%).
Primarily renal excretion of metabolites (60-80%) with less than 1% unchanged drug; biliary/fecal excretion accounts for 20-40%.
Category C
Category C
Nonsteroidal Anti-inflammatory Drug (NSAID)
Nonsteroidal Anti-inflammatory Drug (NSAID)